Stock Scorecard



Stock Summary for Avadel Pharmaceuticals plc (AVDL) - $10.70 as of 11/20/2024 7:47:06 PM EST

Total Score

6 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AVDL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AVDL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AVDL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AVDL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AVDL (37 out of 90)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for AVDL

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference 11/13/2024 1:00:00 PM
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - Avadel Pharmaceuticals ( NASDAQ:AVDL ) 11/13/2024 1:00:00 PM
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation 10/31/2024 11:00:00 AM
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Carvana ( NYSE:CVNA ) 10/31/2024 10:52:00 AM
Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , ANI Pharmaceuticals ( NASDAQ:ANIP ) 10/18/2024 6:38:00 PM
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz 10/18/2024 1:38:00 PM
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker 10/18/2024 9:21:00 AM
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ ( sodium oxybate ) Extended-Release Oral Suspension ( CIII ) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy 10/17/2024 1:41:00 PM
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing ( sodium oxybate ) Extended-Release Oral Suspension ( CIII ) - Avadel Pharmaceuticals ( NASDAQ:AVDL ) 9/3/2024 12:00:00 PM
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences 8/28/2024 12:00:00 PM

Financial Details for AVDL

Company Overview

Ticker AVDL
Company Name Avadel Pharmaceuticals plc
Country USA
Description Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 10.70
Price 4 Years Ago 6.68
Last Day Price Updated 11/20/2024 7:47:06 PM EST
Last Day Volume 1,184,797
Average Daily Volume 1,293,527
52-Week High 19.09
52-Week Low 10.41
Last Price to 52 Week Low 2.79%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -11.26
Free Cash Flow Ratio 15.74
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.97
Total Cash Per Share 0.68
Book Value Per Share Most Recent Quarter 0.98
Price to Book Ratio 13.84
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 7.48
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 96,270,000
Market Capitalization 1,030,089,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.40%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -16.59%
Reported EPS 12 Trailing Months -1.09
Reported EPS Past Year -0.47
Reported EPS Prior Year -2.01
Net Income Twelve Trailing Months -72,575,000
Net Income Past Year -160,276,000
Net Income Prior Year -137,464,000
Quarterly Revenue Growth YOY 2,674.00%
5-Year Revenue Growth -44.07%
Operating Margin Twelve Trailing Months -0.31

Balance Sheet

Total Cash Most Recent Quarter 65,807,000
Total Cash Past Year 105,111,000
Total Cash Prior Year 96,499,000
Net Cash Position Most Recent Quarter -27,332,000
Net Cash Position Past Year 13,497,000
Long Term Debt Past Year 91,614,000
Long Term Debt Prior Year 91,614,000
Total Debt Most Recent Quarter 93,139,000
Equity to Debt Ratio Past Year 0.49
Equity to Debt Ratio Most Recent Quarter 0.44
Total Stockholder Equity Past Year 87,739,000
Total Stockholder Equity Prior Year -21,145,000
Total Stockholder Equity Most Recent Quarter 74,663,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -82,809,006
Free Cash Flow Per Share Twelve Trailing Months -0.86
Free Cash Flow Past Year -128,511,000
Free Cash Flow Prior Year -71,020,000

Options

Put/Call Ratio 0.01
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.32
MACD Signal 0.13
20-Day Bollinger Lower Band 10.83
20-Day Bollinger Middle Band 14.43
20-Day Bollinger Upper Band 18.03
Beta 1.63
RSI 31.75
50-Day SMA 15.11
150-Day SMA 10.74
200-Day SMA 10.15

System

Modified 11/20/2024 6:33:26 PM EST